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Abstract
Background and Objectives Dalbavancin is a novel,
once-weekly glycopeptide antibiotic approved for treat-
ment of acute bacterial skin infections. Given the impor-
tance of understanding any pharmacokinetic variability
across different patient populations, a double-blind, pla-
cebo-controlled study was conducted to evaluate the
pharmacokinetics, safety, and tolerability of a single
500-mg and a single 1000-mg intravenous dose of dalba-
vancin in healthy Japanese subjects.
Methods Ten subjects received intravenous dalbavancin
1000 mg, five subjects received intravenous dalbavancin
500 mg, and three subjects received intravenous placebo.
Results After a single infusion of dalbavancin, the max-
imal plasma concentration (Cmax) and area under the
plasma concentration–time curve (AUC) increased in a
proportional manner from 500 mg to 1000 mg (Cmax:
157 lg/ml and 299 lg/ml; AUClast: 10,850 lgh/ml and
22,679 lgh/ml, on the 500-mg and 1000-mg regimens,
respectively) with low inter-subject variability. The mean
terminal phase half-life (t1/2) was 204 and 193 h after the
500-mg and 1000-mg dose, respectively. Clearance and
volume of distribution were similar for the two dose con-
centrations. Treatment-emergent adverse events reported
were considered to be of mild intensity. There were no
relevant changes in laboratory values or vital signs over
time in subjects in either treatment group.
Conclusions Overall, dalbavancin 500 mg and dalba-
vancin 1000 mg, administered as a single 30-min infusion,
was well tolerated in this population and resulted in plasma
exposures similar to those in non-Asians.
Key Points
Dalbavancin demonstrated dose-proportional
pharmacokinetics in Japanese patients and is well
tolerated.
The pharmacokinetic profile in Japanese patients is
similar to that of non-Asian subjects.
1 Introduction
Dalbavancin is a novel, semisynthetic, lipoglycopeptide
antibiotic with in vitro and in vivo activity against Gram-
positive pathogens, including a minimal inhibitory con-
centration (MIC) required to inhibit the growth of 90 % of
the isolates (MIC90) for Staphylococcus aureus of 0.06
lg/ml [1]. Dalbavancin has a terminal half-life (t1/2) of
2 weeks, related in part to 93 % protein binding, and
reduces the bacterial inoculum in animal models when
administered as larger, less frequent doses, as compared
with smaller, more frequent doses [2]. Pharmacokinetic
studies have demonstrated that plasma concentrations
obtained after once-weekly dosing of dalbavancin provide
mean total and calculated free plasma concentrations above
the S. aureus bactericidal concentration for 7–14 days [3].
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Efficacy was shown in a development program that inclu-
ded four trials involving 1086 patients with skin infection
[4–7].
Dalbavancin, like other glycopeptides, binds to the D-
ala-D-ala terminus of pentapeptides in nascent peptidogly-
can located within the bacterial cell wall [8], thus pre-
venting cross-linking. Dalbavancin does not undergo
cytochrome P450 (CYP) oxidative metabolism and is not a
substrate, inhibitor or inducer of any known CYP-isozyme.
Elimination occurs by means of non-oxidative metabolism
through the hepato-gastrointestinal routes as well as renally
as active intact dalbavancin. The pharmacokinetics of
intravenous dalbavancin have been previously studied in
subjects given single-dose regimens ranging from 70 to
1500 mg, multiple-dose regimens ranging from 480 to
1600 mg administered over 7 days, and once-weekly doses
up to a cumulative total of 4500 mg given over 8 weeks [3,
9, 10]. Plasma concentrations were determined in healthy
volunteers and clinically infected patients. Special popu-
lations have also been evaluated including those with renal
and hepatic impairment, and adolescent children [3, 11–
14]. Dalbavancin pharmacokinetics are linear, exhibit low
inter-individual variability, and are similar in patients and
healthy subjects. The area under the plasma concentration–
time curve (AUC)/MIC ratio appears to be the best pre-
dictor of bacterial eradication and clinical efficacy [2].
There is no evidence of QTc prolongation [17]. The long
elimination t1/2 of dalbavancin of*8.5 days (*200 h) and
its terminal t1/2 of more than 346 h (14.4 days) support the
approved dosing regimen of 1000 mg intravenously fol-
lowed 1 week later by 500 mg, delivered over 30 min [18],
and provide an alternative to current therapy dosing of
patients with acute bacterial skin and skin structure infec-
tion (ABSSSI) [3, 7]. The primary objective of this study
was to evaluate the safety, tolerability, and pharmacoki-
netics of both single 500-mg and single 1000-mg intra-
venous doses of dalbavancin in healthy Japanese subjects
in order to understand if any dose adjustment in this patient
population, relative to non-Asians, is required.
2 Subjects and Methods
2.1 Study Design
The study was conducted between June 2011 and February
2012 as a double-blind, placebo-controlled design in
healthy male and female Japanese volunteers. Eligible
subjects were randomized to receive either intravenous
dalbavancin or intravenous placebo in a 5:1 ratio. The
study consisted of a screening visit (day -28 to day -2), a
check-in visit (Day -1), a treatment phase (days 1–3), and
outpatient visits on day 7, day 14, and day 21 (±1 day).
Subjects returned for an end-of-study visit on day 28
(±1 day). Individual subject participation lasted up to
57 days.
The doses of 1000 and 500 mg of dalbavancin were
chosen based on the dosage regimen for ABSSSI. Subjects
received a single intravenous infusion over 30 min on day
1 of either placebo (250 ml 5 % dextrose for injection,
50 ml sterile water for injection), dalbavancin 500 mg
(250 ml 5 % dextrose for injection, with 25 ml sterile
water for injection, 500 mg dalbavancin with 25 ml sterile
water), or dalbavancin 1000 mg (250 ml 5 % dextrose for
injection, with 50 ml of sterile water for injection, con-
taining 1000 mg dalbavancin). Safety was assessed through
physical examinations, clinical laboratory tests (chemistry,
hematology, and urinalysis), vital sign measurements
(heart rate, blood pressure, respiratory rate, and oral body
temperature), and adverse event and concomitant medica-
tion monitoring.
Subjects were queried regularly on all study days for
any adverse events using non-leading questions. All
adverse events reported spontaneously during the course
of the study were also recorded, as were any clinically
significant clinical laboratory, vital sign, or ECG findings.
Serious adverse events are those that result in death, are
life-threatening, require inpatient hospitalization or pro-
longation of existing hospitalization, result in persistent or
significant disability or incapacity, result in congenital
anomaly or birth defect, or are assessed as being a
medically important event based on medical and scientific
judgment. Blood sampling for plasma dalbavancin con-
centration determination occurred at scheduled time
points.
2.2 Study Subjects
Subjects between the ages of 18 and 55 years who had a
body mass index (BMI) between 18.5 and 30.0 kg/m2 were
considered eligible to participate in the study if they vol-
untarily agreed to participate and signed an internal review
board-approved informed consent form and a supplemental
Japanese consent form prior to performing any of the
screening procedures. Patients enrolled in the study were
born in Japan, with both parents and both sets of grand-
parents also Japanese, had a valid Japanese passport, had
not lived outside Japan for more than 5 years and presently
lived in a Japanese community, generally eating a typical
Japanese diet with lifestyle not notably different from that
experienced in Japan.
Female subjects were surgically sterile (hysterectomy or
bilateral tubal ligation), postmenopausal for at least 2 years
and C50 years of age or confirmed by follicle stimulating
hormone [40 U/L. If of childbearing potential, females
were not pregnant or lactating and agreed to remain
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sexually abstinent from entry through 60 days post-dosing
or have any male partner simultaneously use two proven
effective contraceptive methods. Male patients, without a
vasectomy or with a vasectomy within 6 months prior to
enrollment into the study, were to use a condom and be
instructed that their female partners were to use another
effective form of contraception.
Subjects were not considered eligible to participate in
the clinical study if they had a clinically significant history
or evidence of cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, neurological, immunological,
hematologic, oncologic, or psychiatric disorders as deter-
mined by the investigator or designee or had an estimated
creatinine clearance of B80 ml/min based on the Cock-
croft–Gault formula [15]. In addition, subjects were
excluded if any concurrent disease or condition was present
that, in the opinion of the investigator, would have made
the subject unsuitable for participation in the clinical study,
the subject had an aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) [29 the upper limit of
normal (ULN), total bilirubin[29 ULN, alkaline phos-
phatase (AP)[ 29 ULN, hemoglobin\12.0 g/dl, or any
significant clinical, laboratory, or ECG findings at baseline.
Female subjects who were breastfeeding, planning a
pregnancy during the course of the study, or who had a
positive serum pregnancy test at screening or Day-1 were
excluded, as were subjects having a history of alcohol or
illicit drug abuse within 2 years of entry, those regular
alcohol intake exceeded 24 ounces of beer or the equivalent
per day, or who had a positive breath test for ethanol.
Other exclusion criteria at screening or Day-1 included:
positive test for hepatitis B surface antigen, hepatitis C
antibody, human immunodeficiency virus antibody, posi-
tive urine drug test, smoking more than 10 cigarettes a day,
recent donation of[500 ml of blood or blood products,
inability to abstain from the use of over-the-counter med-
ications, prescription medications, or herbal remedies, or
use of an investigational drug within the last 28 days.
Subjects with known hypersensitivity or intolerance to a
glycopeptide, lipoglycopeptide, or any constituent of dal-
bavancin were excluded. Overall general health was
determined by pre-study medical evaluation and principal
investigator discretion.
2.3 Administration of the Investigational Medicinal
Product
Subjects received a 300-ml intravenous infusion of the
active solution containing 500 or 1000 mg of dalbavancin
or the placebo solution over 30 min (-2 to ?10 min). The
intravenous line was flushed with 5 % dextrose solution
(20–30 ml) at the end of the infusion to ensure delivery of
the entire dose. The intravenous line was inserted in the
contra-lateral arm used to obtain blood draws for safety and
pharmacokinetic sampling.
2.4 Blinding
The clinical study was performed in a double-blind man-
ner. With the exception of unblinded pharmacy staff, nei-
ther the study subjects nor the clinical staff knew the
treatment each subject received. Unblinded pharmacy staff
covered the infusion bags with amber-colored bags to mask
the slight color difference between dalbavancin and pla-
cebo solutions. The amber-colored bags were secured with
staples or tamper-evident tape to prevent unblinding. The
study blind was not to be broken except in a medical
emergency where knowledge of the administration of dal-
bavancin would have affected the treatment of the emer-
gency. The decision to break the blind was to be made on a
case-by-case basis at the discretion of the principal inves-
tigator in collaboration with the Sponsor Medical Monitor.
The applicable standard operating procedure was to be
followed for blind-breaking procedures. After database
lock, the overall randomization code was broken only for
reporting purposes.
2.5 Pharmacokinetic Analyses
No efficacy or pharmacodynamic endpoints were evaluated
in this clinical study.
Pharmacokinetic data were to be analyzed and presented
according to the statistical analysis plan. The individual
subject concentration–time data were listed and displayed
graphically on linear and log scales. The non-compart-
mental pharmacokinetic parameters described later in this
section were calculated using WinNonlin Professional
Version 5.2 (Certara, L.P, Princeton, NJ, USA). All phar-
macokinetic parameters were calculated from the concen-
tration–time data as described. All individual parameter
estimates were to be calculated based on the actual dose
administered with the actual pharmacokinetic sampling
times recorded in the case report form. For descriptive
statistics, the nominal sampling time was to be used. Any
subjects with missing concentration data were included in
the pharmacokinetics analysis set provided that, in the
opinion of the pharmacokinetic analyst, a complete set of
pharmacokinetic parameters could be calculated. Concen-
trations below the lower limit of quantification (LLOQ)
were substituted by 1/2 LLOQ value prior to the calcula-
tion of the summary statistics.
The following were calculated using the linear up/log-
arithmic down trapezoidal method: AUC, AUC from time
zero until the last quantifiable concentration (AUClast),
AUC from time zero through day 7 (AUC0–7 days), and
AUC from time zero to day 14 (AUC0–14 days). AUC from
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time zero (predose) to infinite time (AUC0–?) was calcu-
lated using the following equation: AUC0–? =
AUClast ? Ct/kz, where Ct is the last quantifiable concen-
tration and kz is the terminal elimination rate constant.
Percentage of AUC0–? obtained by extrapolation
(AUC%extrap) was calculated as (1 - [AUClast/AUC0–
?]) 9 100. The terminal elimination rate constant was
estimated at terminal phase by linear regression of con-
centration versus time data presented in a log-linear scale.
Only those data points that were judged to describe the
terminal log-linear decline were used in the regression. A
minimum number of three data points in the terminal phase
were used in calculating kz with the line of regression
starting at any post-Cmax data point [maximal plasma
concentration (Cmax) was not to be part of the regression
slope]. Clearance (CL) was calculated as dose/AUC0–?.
The volume of distribution (Vd) was calculated as CL/kz.
Corrections for free drug portion of dalbavancin were not
made; rather, all values reported are total drug concentra-
tions for dalbavancin.
2.6 Sampling Scheme
Blood was sampled pre-dose and at end of infusion, and 1,
2, 4, 12, 24, and 48 h post-dose, as well as on Days 7, 14,
21 (±1 day), and 28 (±1 day) at approximately the time of
Day 1 dosing. Ten milliliters of blood was collected in
sodium heparin-containing vacutainers from each subject
at each time point. Samples were cooled by an ice bath or
cooling device until processed, centrifuged within 30 min
of collection at approximately 1500 g and 4 C for 10 min,
and then returned to an ice bath or cooling device. Plasma
was evenly divided and transferred into duplicate
polypropylene tubes. Approximately 2 ml of plasma per
tube was required. Immediately after separation samples
were stored and frozen at approximately -20 C or below
until shipment to the bioanalytical laboratory. Plasma was
analyzed by liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) validated for dalbavancin in the
linear range from 0.5 lg/ml to 500 lg/ml using 50 ll of
K2 EDTA plasma [16]. The pharmacokinetic parameters
listed in this section were calculated from the plasma
concentration–actual time profiles. The non-compartmental
analysis was performed using WinNonlin Version 5.2.
Formal sample size calculations were not performed. A
total of 18 subjects were considered suitable to achieve the
study objectives.
2.7 Protocol Amendments
Two protocol amendments were issued during the study.
The first was issued due to an update of the wording of the
serious adverse event definition of the United States Food
and Drug Administration Safety Reporting Requirements,
and the second was to add an additional six subjects of




A single intravenous infusion of dalbavancin 500 mg was
administered to five healthy Japanese subjects and
1000 mg to ten healthy Japanese subjects. Baseline
demographic characteristics are provided in Table 1.
Pharmacokinetic parameters following the administration
of dalbavancin 1000-mg and 500-mg regimens are sum-
marized in Tables 2 and 3, respectively. Peak plasma
concentrations were reached following the end of the
infusion. Mean concentration versus time plots in linear
scales for those who received the 1000-mg or 500-mg dose
regimens are illustrated in Figs. 1 and 2, respectively.
After a single intravenous infusion of dalbavancin, Cmax
and AUC increased in a proportional manner from the
500-mg dose to the 1000-mg dose. Plasma dalbavancin
geometric mean (±SD) Cmax increased from 157 ± 18
lg/ml after the 500-mg dose to 299 ± 36 lg/ml for the
1000-mg dose level and occurred at a median time of 0.5 h
for the 500-mg dose to 1 h for the 1000-mg dose post-start
of infusion. Inter-subject variability was relatively low with
a coefficient of variation (CV%) of 11.2 % for the 500-mg
dose and 12.0 % for the 1000-mg dose level. Geometric
mean AUClast increased from 10,850 ± 1781 lgh/ml after
the 500-mg dose to 22,679 ± 1982 lgh/ml for the
1000-mg dose level. Similarly, geometric mean AUC0–7,
AUC0–14, and AUC0–? increased from 5756 ± 671 lgh/
ml, 8554 ± 1148 lgh/ml, and 12,042 ± 2460 lgh/ml
after the 500-mg dose to 12,155 ± 1466 lgh/ml,
18,028 ± 1834 lgh/ml, and 24,745 ± 2093 lgh/ml for
the 1000-mg dose level. Exposure measured in terms of the
AUC also showed relatively low inter-subject variability,
ranging from 11.6 to 20.1 % for the 500-mg dose and from
8.4 to 12.0 % for the 1000-mg dose level. The mean
AUC%extrap ranged from 8.34 % for the 1000-mg dose to
9.83 % for the 500-mg dose, indicating reliable AUC0-?
estimations for both dose concentrations. Based on mean
partial AUCs, the percentage of total exposure (i.e., AUC0–
?) were similar for the two dose concentrations, with
approximately 47 % after 7 days and 70 % after 14 days
for the 500-mg dose and approximately 49 % after 7 days
and 73 % after 14 days for the 1000-mg dose. The mean
terminal phase t1/2 was consistent across the dose concen-
trations: 204 h (range 182–240 h) after the 500-mg dose
and 193 h (range 162–220 h) for the 1000-mg dose level.
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Table 1 Summary of
demographics of the Japanese
subjects included in this study










Male (n) 7 1 5 1
Female (n) 3 1
Race
Asian (n) 10 2 5 1
Age (y)
Mean (SD) 33.8 (8.2) NC 41.0 (12.3) NC
Range 25–50 NC 26–54 NC
Height (cm)
Mean (SD) 166.0 (7.1) NC 158.4 (4.9) NC
Range 152–180 NC 155–167 NC
Weight (kg)
Mean (SD) 59.0 (7.4) NC 60.7 (12.7) NC
Range 48.1–68.9 NC 49.1–81.8 NC
BMI (kg/m2)
Mean (SD) 21.4 (1.6) NC 24.0 (3.4) NC
Range 19.2–24.4 NC 20.2–29.3 NC
BMI body mass index, NC not calculated, SD standard deviation

















ArithMean 0.81 301.2 12,230 18,110 22,756 24,824 193.1 40.54 11,301
CV% 31.8 12.0 12.0 10.1 8.7 8.4 9.1 8.4 12.9
GeoMeana 0.76 299.2 12,155 18,028 22,679 24,745 192.3 40.41 11,213
Minimum 0.50 248.0 10,239 15,250 19,666 21,853 161.7 34.83 89,99
Maximum 1.02 353.0 15,511 21,940 26,638 28,715 220.3 45.76 13,691
ArithMean arithmetic mean, CV coefficient of variation, GeoMean geometric mean, Tmax time to maximum concentration, Cmax maximum
plasma concentration, AUC area under the plasma concentration–time curve, t1/2 half-life, CL clearance, Vd volume of distribution
a Median for Tmax



















ArithMean 0.50 158.2 5790 8619 10,970 12,242 204.0 42.22 12,182
CV% 0.0 11.2 11.6 13.3 16.2 20.1 13.3 20.5 9.8
GeoMeana 0.50 157.3 5756 8554 10,850 12,042 202.6 41.52 12,138
Minimum 0.50 129.0 4683 6864 8527 9230 181.7 32.95 11,412
Maximum 0.50 173.0 6389 9725 12,697 15,177 240.1 54.17 14,205
ArithMean arithmetic mean, CV coefficient of variation, GeoMean geometric mean, Tmax time to maximum concentration, Cmax maximum
plasma concentration, AUC area under the plasma concentration–time curve, t1/2 half-life, CL clearance, Vd volume of distribution
a Median for Tmax
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Clearance (CL) and volume of distribution were similar for
the two dose concentrations. Mean CL was 42.2 ml/h
(range 32.9–54.1 ml/h) for the 500 mg dose and 40.5 ml/h
(range 34.8–45.8 ml/h) for the 1000-mg dose, and mean Vd
was 12,182 ml (range 11,412–14,205 ml) for the 500-mg
dose and 11,301 ml (range 8999–13,691 ml) for the
1000-mg dose. Compartmental analysis was performed as
an additional exercise to establish the probable error in
determination of Cmax, Tmax, and AUC0–? due to the fact
that in seven subjects receiving active drug (1000 mg), the
end-of-infusion sample was taken just prior to the com-
pletion of the infusion. The percentage deviation between
this predicted value and the observed value obtained by
non-compartmental analysis (predicted/observed) did not
exceed 10.7 % in any subject for Cmax (average Cmax
deviation 7 % in seven subjects). Positive deviations were
also recorded in two of the three remaining actively treated
subjects in the cohort who had end-of infusion samples
Fig. 1 Mean (±SD) plasma
concentrations of intravenous
dalbavancin 1000 mg
Fig. 2 Mean (±SD) plasma
concentrations of intravenous
dalbavancin 500 mg
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correctly taken. The AUC did not deviate significantly with
a maximum recorded individual subject AUC0–? deviation
of -3.3 % (average AUC0–? deviation was 2.0 % in seven
subjects). Due to the small deviations recorded, it can be
concluded that the pharmacokinetic samples taken during
infusion did not significantly affect study conclusions.
3.2 Safety and Tolerability
Safety and tolerability were assessed and a summary of the
demographics of the safety population is shown in Table 4.
In the 500-mg dose group, five subjects received a single
500-mg infusion of dalbavancin and one subject received a
single infusion of placebo. In the 1000-mg dose group, ten
subjects received a single 1000-mg infusion of dalbavancin
and two subjects received a single infusion of placebo. In
the 500-mg dose group, two of the five subjects (40 %)
receiving 500-mg dalbavancin experienced a single treat-
ment-emergent adverse event (TEAE), and the one subject
(100 %) receiving placebo experienced two TEAEs. In the
dalbavancin group, these consisted of dyspepsia (mild) and
dizziness (mild); dyspepsia was considered by the inves-
tigator to be not related and dizziness unlikely to be related
to study medication. The subject receiving placebo repor-
ted eczema of mild intensity and cellulitis of moderate
intensity, both of which were considered by the investi-
gator to be not related to study medication. All TEAEs of
the dalbavancin group were resolved at the end of the
study.
For the 1000-mg dose group, a total of eight TEAEs
were reported by three of the ten subjects (30 %) receiving
dalbavancin; none of the two subjects receiving placebo
reported a TEAE. The reported TEAEs consisted of pal-
pitations, diarrhea (twice reported by one subject),
dizziness, headache, oropharyngeal pain, blister, and rash.
Of these, rash and diarrhea were considered by the inves-
tigator to be possibly related to study medication. All other
TEAE reports were considered unlikely to be related. The
palpitation TEAE was not resolved at the end of the study,
whereas all other TEAEs had resolved. None of the sub-
jects died, no serious adverse event occurred, and no sub-
ject discontinued study medication due to a TEAE.
Mean and median values of all parameters of clinical
chemistry and hematology did not show any
notable changes from baseline at any post-dose time point.
None of the individual laboratory values of clinical
chemistry, hematology, and urinalysis showed any relevant
changes from baseline in any dose group or for placebo. A
few isolated, abnormal values of some of the parameters
were found in both dose groups and for placebo, but none
were considered by the investigator to be of clinical sig-
nificance. No clinically relevant, abnormal laboratory val-
ues were reported in any dose group or for placebo.
4 Discussion
The primary objectives of this study were to evaluate the
safety, tolerability, and pharmacokinetics of single 500-mg
and 1000-mg intravenous doses of dalbavancin in healthy
male and female adult Japanese subjects. The results from
this trial have confirmed that the pharmacokinetics of
dalbavancin are similar in Japanese patients to those pre-
viously studied. The geometric mean dalbavancin Cmax and
AUC increased in a proportional manner from the 500-mg
to the 1000-mg dose level. The mean t1/2 was consistent at
193–204 h across two dose concentrations, and the CL and
Vd were not dose dependent; mean CL ranged from 40.5 to
Table 4 Summary of treatment-emergent adverse events (TEAEs)








No. of subjects with at least one TEAE 3 (30 %) 0 2 (40 %) 1 (100 %)
Palpitations 1 0 0 0
Diarrhea 1 0 0 0
Dyspepsia 0 0 1 0
Cellulitis 0 0 0 1
Dizziness 1 0 1 0
Headache 1 0 0 0
Oropharyngeal pain 1 0 0 0
Blister 1 0 0 0
Rash 1 0 0 0
Eczema 0 0 0 1
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42.2 ml/h and mean Vd ranged from 11,301 to 12,182 ml
across two dose concentrations. The TEAEs in subjects
receiving dalbavancin in both dose groups were considered
to be of mild intensity and the sole adverse event of
moderate intensity was reported in a subject receiving
placebo and, while reported from a small number of sub-
jects, is consistent with the experience in recent phase III
trials [4, 7]. There were no relevant changes in laboratory
values or vital signs over time in subjects in either treat-
ment group. Overall, dalbavancin 500 mg and dalbavancin
1000 mg, administered as single 30-min infusions, were
well tolerated in healthy male and female adult Japanese
subjects.
The measured t1/2 in the Asian patients enrolled in this
study was 193–204 h (8.0–8.5 days) consistent with previ-
ous studies in non-Asians in which follow-up measurements
were taken out for 28 days after dosing [3]. Other studies
with follow-up periods as long as 70 days [19] have docu-
mented a terminal t1/2 as long as 15.5 days, an observation
consistent with the low clearance of dalbavancin.
Dalbavancin was the first long-acting lipoglycopeptide
to be approved for use in the USA, in May 2014. Its long
t1/2 and relatively short infusion time allows for once-
weekly dosing for treatment of acute bacterial skin and skin
structure infections known or suspected to involve Gram-
positive pathogens, while improving the experience of
infected patients, allowing the avoidance of a need for a
central line and the possibility of either preventing hospi-
talization in suitable patients or allowing an earlier
discharge.
5 Conclusions
This study demonstrated in healthy Japanese volunteers
that the Cmax and AUC of dalbavancin increased propor-
tionally from the 500-mg to the 1000-mg dose level and
were associated with a consistent t1/2 of 193–204 h as has
been described in other patient populations. This study
supports the use of dalbavancin administered once weekly
for the treatment of Gram-positive infections in the Japa-
nese population.
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